GRAIL reported strong third-quarter performance, with a 39% increase in Gallery volume and a 29% increase in revenue year-over-year, reflecting robust uptake and strategic developments in key markets.
- Gallery tests are growing in adoption, with approximately 420,000 tests sold across over 16,000 healthcare providers.
- Strategic collaboration announced with Samsung to commercialize Gallery in South Korea and other Asian markets, alongside a $110 million equity investment from Samsung.
- Successfully launched Gallery in Canada through a partnership with MedCan, expanding market presence.
- Completed a $325 million private placement to strengthen financial position as the company progresses towards key milestones.
- Positive results from PATHFINDER II study showcased substantial cancer detection improvements, underscoring Gallery’s effectiveness in early cancer diagnosis.
Community Discussion